- Home
- AGEN vs XTNT Comparison
AGEN vs XTNT Comparison
Compare AGEN & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- XTNT
- Stock Information
- Founded
- AGEN 1994
- XTNT N/A
- Country
- AGEN United States
- XTNT United States
- Employees
- AGEN N/A
- XTNT N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AGEN Health Care
- XTNT Health Care
- Exchange
- AGEN Nasdaq
- XTNT Nasdaq
- Market Cap
- AGEN 52.6M
- XTNT 60.9M
- IPO Year
- AGEN 2000
- XTNT N/A
- Fundamental
- Price
- AGEN $2.91
- XTNT $0.50
- Analyst Decision
- AGEN Buy
- XTNT Strong Buy
- Analyst Count
- AGEN 4
- XTNT 1
- Target Price
- AGEN $8.00
- XTNT $3.00
- AVG Volume (30 Days)
- AGEN 830.5K
- XTNT 125.0K
- Earning Date
- AGEN 05-12-2025
- XTNT 05-12-2025
- Dividend Yield
- AGEN N/A
- XTNT N/A
- EPS Growth
- AGEN N/A
- XTNT N/A
- EPS
- AGEN N/A
- XTNT N/A
- Revenue
- AGEN $103,463,000.00
- XTNT $117,267,000.00
- Revenue This Year
- AGEN $4.03
- XTNT $11.64
- Revenue Next Year
- AGEN $5.57
- XTNT $7.59
- P/E Ratio
- AGEN N/A
- XTNT N/A
- Revenue Growth
- AGEN N/A
- XTNT 28.44
- 52 Week Low
- AGEN $1.38
- XTNT $0.33
- 52 Week High
- AGEN $19.69
- XTNT $0.88
- Technical
- Relative Strength Index (RSI)
- AGEN 59.81
- XTNT 53.96
- Support Level
- AGEN $2.87
- XTNT $0.39
- Resistance Level
- AGEN $3.16
- XTNT $0.54
- Average True Range (ATR)
- AGEN 0.35
- XTNT 0.05
- MACD
- AGEN 0.02
- XTNT 0.01
- Stochastic Oscillator
- AGEN 56.25
- XTNT 76.47
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.